WO2015121458A3 - Utilisations de compositions comprenant du bifidobacterium animalis ssp. lactis lmg p-28149 - Google Patents

Utilisations de compositions comprenant du bifidobacterium animalis ssp. lactis lmg p-28149 Download PDF

Info

Publication number
WO2015121458A3
WO2015121458A3 PCT/EP2015/053166 EP2015053166W WO2015121458A3 WO 2015121458 A3 WO2015121458 A3 WO 2015121458A3 EP 2015053166 W EP2015053166 W EP 2015053166W WO 2015121458 A3 WO2015121458 A3 WO 2015121458A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
bifidobacterium animalis
animalis ssp
lmg
overweight
Prior art date
Application number
PCT/EP2015/053166
Other languages
English (en)
Other versions
WO2015121458A2 (fr
Inventor
Johan QUINTENS
Jehan LIENART VAN LIDTH DE JEUDE
Corinne Grangette
Bruno Pot
Kassem MAKKI
Isabelle Wolowczuk
Jeanne ALARD
Véronique LEHRTER-VALENTI
Original Assignee
Vesale Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vesale Pharma Sa filed Critical Vesale Pharma Sa
Priority to US15/118,077 priority Critical patent/US20160354418A1/en
Priority to EP15705283.8A priority patent/EP3104868A2/fr
Priority to CA2938790A priority patent/CA2938790A1/fr
Priority to BR112016018283A priority patent/BR112016018283A2/pt
Priority to CN201580008081.2A priority patent/CN106535908A/zh
Priority to RU2016133852A priority patent/RU2673341C2/ru
Priority to JP2016551748A priority patent/JP2017506637A/ja
Publication of WO2015121458A2 publication Critical patent/WO2015121458A2/fr
Publication of WO2015121458A3 publication Critical patent/WO2015121458A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/515—Animalis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Abstract

Composition à base d'au moins probiotique pour son utilisation dans le traitement curatif de la prise de poids corporel chez l'être humain en surpoids et/ou dans le traitement préventif de la prise de poids corporel chez l'être humain en surpoids ou ayant été en surpoids, ledit probiotique étant Bifidobacterium animalis ssp. Iactis n° LMG P-28149.
PCT/EP2015/053166 2014-02-14 2015-02-13 Composition comprenant du bifidobacterium animalis ssp. lactis WO2015121458A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US15/118,077 US20160354418A1 (en) 2014-02-14 2015-02-13 Use of compositions comprising bifidobacterium animalis ssp. lactis lmg p-28149
EP15705283.8A EP3104868A2 (fr) 2014-02-14 2015-02-13 Utilisations de compositions comprenant du bifidobacterium animalis ssp. lactis lmg p-28149
CA2938790A CA2938790A1 (fr) 2014-02-14 2015-02-13 Composition comprenant du bifidobacterium animalis ssp. lactis
BR112016018283A BR112016018283A2 (pt) 2014-02-14 2015-02-13 Composição que compreende bifidobacterium animalis ssp. lactis
CN201580008081.2A CN106535908A (zh) 2014-02-14 2015-02-13 包括动物双歧杆菌亚种乳酸菌lmg p‑28149的组合物
RU2016133852A RU2673341C2 (ru) 2014-02-14 2015-02-13 Применение композиций, содержащих bifidobacterium animalis ssp. lactis lmg p-28149
JP2016551748A JP2017506637A (ja) 2014-02-14 2015-02-13 ビフィドバクテリウム・アニマリス亜種ラクティスを含む組成物

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
BE2014000101 2014-02-14
BEBE2014/0101 2014-02-14
FR1453775 2014-04-25
BEBE2014/0292 2014-04-25
BE2014000292 2014-04-25
FR1453775 2014-04-25

Publications (2)

Publication Number Publication Date
WO2015121458A2 WO2015121458A2 (fr) 2015-08-20
WO2015121458A3 true WO2015121458A3 (fr) 2015-10-08

Family

ID=53800720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/053166 WO2015121458A2 (fr) 2014-02-14 2015-02-13 Composition comprenant du bifidobacterium animalis ssp. lactis

Country Status (1)

Country Link
WO (1) WO2015121458A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109999010B (zh) * 2019-04-23 2021-06-15 河北地邦动物保健科技有限公司 一种益生菌包被微丸及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3423093A4 (fr) * 2016-03-04 2019-11-13 The Regents of The University of California Consortium microbien et utilisations de ce dernier
EP3442550B1 (fr) * 2016-04-14 2024-03-13 International N&H Denmark ApS Bifidobactéries pour réduire la prise d'un aliment, d'une énergie et/ou de poids
JP6862464B2 (ja) * 2016-09-06 2021-04-21 ビージーアイ シェンチェン フィーカリバクテリウム・ロンガム（Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ ｌｏｎｇｕｍ）およびその使用
CN110893194B (zh) * 2019-11-20 2023-03-14 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用
KR102445708B1 (ko) * 2021-12-02 2022-09-23 일동바이오사이언스(주) 비피도박테리움 락티스 idcc 4301을 포함하는 체지방감소용 조성물
CN116590205B (zh) * 2023-07-14 2023-10-03 中国农业大学 一种动物双歧杆菌亚种组合菌剂在减肥制剂制备中的应用

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076615A2 (fr) * 2003-02-27 2004-09-10 Bioneer A/S Composes prtobiotiques immunomodulateurs
WO2006041930A2 (fr) * 2004-10-04 2006-04-20 Nutracea Incorporated Synbiotiques
WO2007085970A2 (fr) * 2006-01-27 2007-08-02 Danisco A/S Emploi d'une souche de micro-organisme dans le traitement des troubles ponderaux
FR2921669A1 (fr) * 2007-09-27 2009-04-03 Biomerieux Sa Milieu de culture de microorganismes comprenant un inhibiteur de bacteriocines.
CN101451117A (zh) * 2008-12-15 2009-06-10 江南大学 一种提高乳酸乳球菌抵御酸胁迫的方法
WO2009071086A2 (fr) * 2007-12-06 2009-06-11 Arla Foods Amba Bactérie probiotique et régulation de l'accumulation de graisse
WO2009153662A1 (fr) * 2008-06-20 2009-12-23 Danisco A/S Nouvelles utilisations des bactéries de l'acide lactique et des bifidobactéries
WO2010081126A2 (fr) * 2009-01-12 2010-07-15 Wyeth Llc Compositions comprenant des composants probiotiques et prébiotiques et des sels minéraux, ainsi que de la lactoferrine
WO2010146568A2 (fr) * 2009-06-19 2010-12-23 Danisco A/S Bifidobactéries pour le traitement du diabète et d'affections apparentées
EP2359838A1 (fr) * 2010-02-02 2011-08-24 Aragan Préparation destinée à traiter l`excès pondéral et les désordres associés et applications de ladite préparation
EP2431044A1 (fr) * 2005-10-07 2012-03-21 Arla Foods Amba Probiotiques pour agir sur le métabolisme des graisses et l'obésité
LU91782B1 (fr) * 2011-01-21 2012-07-23 Vesale Pharma S A Substance probiotique microencapsulee
WO2012101167A1 (fr) * 2011-01-25 2012-08-02 Austrianova Singapore Pte Ltd. Protection de cellules microbiennes contre la dégradation acide
FR2997092A1 (fr) * 2012-10-22 2014-04-25 Fond Mediterranee Infection Utilisation d'un compose antioxydant pour la culture de bacteries sensibles a la tension en oxygene

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076615A2 (fr) * 2003-02-27 2004-09-10 Bioneer A/S Composes prtobiotiques immunomodulateurs
WO2006041930A2 (fr) * 2004-10-04 2006-04-20 Nutracea Incorporated Synbiotiques
EP2431044A1 (fr) * 2005-10-07 2012-03-21 Arla Foods Amba Probiotiques pour agir sur le métabolisme des graisses et l'obésité
WO2007085970A2 (fr) * 2006-01-27 2007-08-02 Danisco A/S Emploi d'une souche de micro-organisme dans le traitement des troubles ponderaux
FR2921669A1 (fr) * 2007-09-27 2009-04-03 Biomerieux Sa Milieu de culture de microorganismes comprenant un inhibiteur de bacteriocines.
WO2009071086A2 (fr) * 2007-12-06 2009-06-11 Arla Foods Amba Bactérie probiotique et régulation de l'accumulation de graisse
WO2009153662A1 (fr) * 2008-06-20 2009-12-23 Danisco A/S Nouvelles utilisations des bactéries de l'acide lactique et des bifidobactéries
CN101451117A (zh) * 2008-12-15 2009-06-10 江南大学 一种提高乳酸乳球菌抵御酸胁迫的方法
WO2010081126A2 (fr) * 2009-01-12 2010-07-15 Wyeth Llc Compositions comprenant des composants probiotiques et prébiotiques et des sels minéraux, ainsi que de la lactoferrine
WO2010146568A2 (fr) * 2009-06-19 2010-12-23 Danisco A/S Bifidobactéries pour le traitement du diabète et d'affections apparentées
EP2359838A1 (fr) * 2010-02-02 2011-08-24 Aragan Préparation destinée à traiter l`excès pondéral et les désordres associés et applications de ladite préparation
LU91782B1 (fr) * 2011-01-21 2012-07-23 Vesale Pharma S A Substance probiotique microencapsulee
WO2012101167A1 (fr) * 2011-01-25 2012-08-02 Austrianova Singapore Pte Ltd. Protection de cellules microbiennes contre la dégradation acide
FR2997092A1 (fr) * 2012-10-22 2014-04-25 Fond Mediterranee Infection Utilisation d'un compose antioxydant pour la culture de bacteries sensibles a la tension en oxygene

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOMHOF M R ET AL: "Combined effects of oligofructose and Bifidobacterium animalis on gut microbiota and glycemia in obese rats", OBESITY MARCH 2014 NATURE PUBLISHING GROUP GBR, vol. 22, no. 3, 1 October 2013 (2013-10-01), pages 763 - 771, XP002733934, ISSN: 1930-7381 *
DATABASE WPI Week 200945, Derwent World Patents Index; AN 2009-K55576, XP002742583 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109999010B (zh) * 2019-04-23 2021-06-15 河北地邦动物保健科技有限公司 一种益生菌包被微丸及其制备方法

Also Published As

Publication number Publication date
WO2015121458A2 (fr) 2015-08-20

Similar Documents

Publication Publication Date Title
WO2015121458A3 (fr) Utilisations de compositions comprenant du bifidobacterium animalis ssp. lactis lmg p-28149
BR112016018283A2 (pt) Composição que compreende bifidobacterium animalis ssp. lactis
HK1226100B (zh) 雙歧桿菌乳酸亞種(bifidobacterium animalis subsp．lactis)cect 8145的新菌株及其用於治療和/或預防超重和肥胖症以及相關疾病的用途
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
WO2018013583A3 (fr) Cocktail de lactobacillus vaginal médicinal
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
EP3787668C0 (fr) Souches bactériennes probiotiques produisant des protéines antimicrobiennes et compositions les comprenant pour le traitement d'infections de clostridium difficile
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2017007654A (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas.
WO2017199022A3 (fr) Compositions de et leurs utilisations
HK1198326A1 (zh) 用於預防或治療上呼吸道感染的鼠李糖乳桿菌和動物雙歧桿菌乳亞種
WO2017121646A8 (fr) Dérivés de 3-(carboxyéthyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-décane
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
MX2017007969A (es) Bacterias de acido lactico y su uso para el tratamiento de mastitis.
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
WO2019022602A8 (fr) Composition pharmaceutique destinée à être utilisée dans le traitement ou la prévention de carences en vitamines et minéraux chez des patients ayant été soumis à une gastrectomie
WO2014096083A3 (fr) Utilisation de microorganismes probiotiques comme agent favorisant la synthèse de mélanine
JP2016003187A5 (fr)
SG11201810993SA (en) Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implantation infections
MY193625A (en) Probiotic composition for treatment or prevention of high blood cholesterol
CL2020001958A1 (es) Composición que comprende nuevas cepas de lactobacillus salivarius y método para la prevención y el tratamiento de otitis e infecciones respiratorias de vías altas.
MX2020013860A (es) Composiciones probioticas y sus usos.
UA93301U (uk) Композиційний біопрепарат для лікування запалення тканин пародонту і корекції асоційованих гастродуоденальних розладів кишечнику у дітей
HUP1600364A2 (en) Food supplement synergetic herbal composition for streng then vitalising human body, especially the muscles of the leg and arm
RS54225B1 (en) Indigenous LACTOBACILLUS strains and their use as probiotics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15705283

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2938790

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016551748

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15118077

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016018283

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2015705283

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015705283

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016133852

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016018283

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160808